Muscle invasive and metastatic bladder cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  Sternberg, C N ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; VINBLASTINE; VINFLUNINE;

AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CYSTECTOMY; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; LUNG METASTASIS; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MONOTHERAPY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

HUMANS; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 33749600353     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl231     Document Type: Article

References (97)

1. Parkin DM, Pisani P, Ferlay J. Global Cancer Statistics. CA Cancer J Clin 1999; 49 (81): 33-64.
2. Stein JP, Lieskovsky G, Cote R et al. Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-term Results in 1.054 Patients. J Clin Oncol 2001; 19 (3): 666-675.
3. Dalbagni G, Genega E, Hashibe M et al. Cystectomy for Bladder Cancer: A Contemporary Series. J Urol 2001; 165 (4): 1111-1116.
4. Bassi P, Ferrante GD, Piazza N et al. Prognostic Factors of Outcome after Radical Cystectomy for Bladder Cancer: A Retrospective Study of a Homogeneous Patient Cohort. J Urol 1999; 161(5): 1494-1497.
5. Ghoneim MA, el-Mekresh MM, el-Baz MA et al. Radical cystectomy for carcinoma of the bladder: Critical evaluation of the results in 1,026 cases. J Urol 1997; 158 (2): 393-399.
6. Sternberg CN. Current perspectives in muscle invasive bladder cancer. Eur J Cancer 2002; 38 (4): 460-467.
7. Sternberg CN. Chemotherapy for local treatment of bladder cancer. Semin Radiat Oncol 2005; 15: 60-65.
8. Sternberg CN, Pansadoro V, Calabrò F et al. Can Patient Selection for Bladder Preservation be Based on Response to Chemotherapy? Cancer 2003; 97 (7): 1644-1652.
9. Herr HW, Scher HI. Surgery of invasive bladder cancer: Is pathologic staging necessary? Semin Oncol 1990; 17: 590-597.
10. Sanchez-Ortiz RF, Huang WC, Mick R et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 2003; 169 (1): 110-115.
11. Stein JP. Contemporary concepts of radical cystectomy and the treatment of bladder cancer. J Urol 2003; 169 (1): 116-117.
12. Millikan R, Dinney C, Swanson D et al. Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial al cystectomy plus adjuvant M-VAC versus cystectomy with bath preoperative and postoperative M-VAC. J Clin Oncol 2001; 19: 4005-4013.
13. Hall MC, Swanson DA, Dinney CP. Complications of radical cystectomy: impact of the timing of perioperative chemotherapy. Urol 1996; 47 (6): 826-830.
14. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349 (9): 859-866.
15. Grossman HB, Natale RB, Tangen CM et al. Errata Corrige for: 'Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer' published in N Engl J Med. 2003 Aug 28; 349 (9): 859-66. N Engl J Med 2003; 349 (9): 1880.
16. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. Lancet 1999; 354 (9178): 533-540.
17. Hall RR. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vintilastine (V) chemotherapy for muscle-invasive bladder cancer. Intl Collaboration of Trialists of the MRC Advanced Bladder Cancer Group. Proc Ann Meet Am Soc Clin Oncol 21 (1), 178a. 2002.
18. Malmstrom PU, Rintala E, Wahlqvist R et al. Five year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy. J Urol 1996; 155: 1903-1906.
19. Sherif A, Rintala E, Mestad O et al. Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer - Nordic cystectomy trial 2. Scand J Urol Nephrol 2002; 36 (6): 419-425.
20. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48 (2): 202-205.
21. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 2003; 361 (9373): 1927-1934.
22. Sherif A, Holmberg L, Rintala E et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two Nordic studies. Nordic Urothelial Cancer Group. Eur Urol 2004; 45 (3): 297-303.
23. Herr HW, Faulkner JR, Grossman HB et al. Surgical factors Influence bladder cancer outcomes: A cooperative group report. J Clin Oncol 2004; 22 (14): 2781-2789.
24. Wallace DM, Raghavan D, Kelly KA et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67: 608-615.
25. Coppin CM, Gospodarowicz MK, James K et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14 (11): 2901-2907.
26. Martinez Pineiro A Gonzalez Martin M, Arocena F. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder prospective randomized phase III study. J Urol 1995; 153: 964-973.
27. Natale RB, Grossman HB, Blumenstein B et al. SWOG 8710 (INT-0080): Randomized Phase III Trial of Neoadjuvant M-VAC and Cystectomy versus Cystectomy alone in Patients with Locally Advanced Bladder Cancer. Proc Am Soc Clin Oncol 2001; 20 (1): 2a.
28. Bassi P, Pagano F, Pappagallo G et al. Neo-adjuvant M-VAC of invasive bladder cancer: The G.U.O.N.E. multicenter phase III trial. Eur Urol 1998; 33 (Suppl 1): 142.
29. GISTV (Italian Bladder Cancer Study Group). Neoadjuvant Treatment for Locally Advanced Bladder Cancer: A Randomized Prospective Clinical Trial. J Chemother 1996; 8: 345-346.
30. Orsatti M, Curotto A, Canobbio L. Alternating chemo-radiotherapy in bladder cancer: A conservative approach. Int J Radiation Oncology Biol Phys 1995; 33: 173-178.
31. Abol-Enein H, El Makresh M, El Baz M, Ghoneim M. Neo-adjuvant chemotherapy in treatment of invasive transitional bladder cancer: A controlled, prospective randomised study. Br J Urol 1997; 80 (suppl 2): 49.
32. Hautmann RE. Urinary diversion: Ileal conduit to neobladder. J Urol 2003; 169 (3): 834-842.
33. Herr HW. Transurethral Resection of Muscle-Invasive Bladder Cancer: 10-Year Outcome. J Clin Oncol 2001; 19 (1): 89-93.
34. Solsona E, Iborra I, Ricos JV et al. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: Long-term followup of a prospective study. J Urol 1998; 159: 95-99.
35. Herr HW. Uncertainty and outcome of invasive bladder tumors. Urol Oncol 1996; 2: 92-95.
36. Hall RR, Newling DW, Ramsden PD et al. Treatment of invasive bladder cancer by local resection and high dose methotrexate. Br J Urol 1984; 56: 668-672.
37. Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder sparing surgery for invasive bladder cancer: Ten-year outcome. J Clin Oncol 1998; 16 (4): 1298-1301.
38. Thomas DJ, Roberts JT, Hall RR, Reading J. Radical transurethral resection and chemotherapy in the treatment at muscle invasive bladder cancer: A long-term follow-up. Br J Urol 1999; 83: 432-437.
39. Angulo JC, Sanchez-Chapado M, Lopez JI, Flores N. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: Multvariate analysis on prognostic factors. J Urol 1996; 155 (6): 1897-1902.
40. Sternberg CN, Pansadoro V, Calabrò F et al. Neo-adjuvant Chemotherapy and Bladder Preservation in Locally Advanced Transitional Cell Carcinoma of the Bladder. Ann Oncol 1999; 10 (11): 1301-1305.
41. De la Rosa F, Garcia-Carbonero R, Passas J et al. Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: Long-term followup of a prospective study. J Urol 2002; 167: 2413-2418.
42. Shipley WU, Kaufman DS, Tester WJ et al. Overview of bladder cancer trials in the Radiation Therapy Onoology Group. Cancer 2003; 97 (8 Suppl): 2115-2119.
43. Sauer R, Birkenhake S, Kühn R et al. Muscle-Invasive Bladder Cancer: Transurethral Resection and Radiochemotherapy as an Organ-Sparing Treatment Option. In: Petrovich Z, Baert L, Brady LW. Carcinoma of the bladder. Springer, 1998: 205-214.
44. Housset M, Dufour B, Maulard-Durdux C et al. Concomitant fluorouracil (5-FU)-cisplatin (CDDP) and bifractonated split course radiation therapy (BSCRT) for invasive bladder cancer. Proc Am Soc Clin Oncol 1997; 16: 319A.
45. Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: A prospective comparative trial. J Urol 1991; 145: 459-467.
46. Storckle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 nad pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy results of a controlled prospective study. J Urol 1992; 148: 302-307.
47. Stockle M, Meyenburg W, Wellek S. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long term results of a controlled prospective study and further clinical experience. J Urol 1995; 153: 47-52.
48. Lehmann J, Franzaring L, Thuroff J et al. Complete long-term survival data from a trial of adjuvant chemotherapy vs. control after radical cystectomy for locally advanced bladder cancer. Brit J Urol International 2006; 97: 42-7.
49. Otto T, Börgemann C, Krage S et al. Adjuvant Chemotherapy in locally advanced Bladder Cancer (PT3/PN1-2,M0) - A Phase III Study. Eur Urol 2001; 39 (Suppl 5), 147.
50. Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: What we do not know and why. Ann Onool 2000; 11 (7): 851-856.
51. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patent data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48 (2): 189-99; discussion 199-201.
52. Cote RJ, Dunn MD, Chatterjee SJ et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58: 1090-4.
53. Loehrer P, Einhorn LH, Elson PJ et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patents with metastatic urothelial carcinoma: A Cooperative Group Study. J Clin Oncol 1992; 10: 1066-1073.
54. Logothetis CJ, Dexeus F, Finn L et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumors. J Clin Oncol 1990; 8: 1050-1055.
55. Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial tumors. J Urol 1985; 133: 403-407.
56. Sternberg CN, Yagoda A, Scher HI et al. M-VAC for advanced transitional cell carcinoma of the urothelium: Efficacy, and patterns of response and relapse. Cancer 1989; 64: 2448-2458.
57. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17 (10): 3173-81.
58. Dodd PM, McCaffrey JA, Herr H et al. Outcome of Postchemotherapy Surgery After Treatment with Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Unresectable or Metastatic Transitional Cell Carcinoma. Clin Oncol 1999; 17 (8): 2546.
59. Vogelzang NJ. Future directions for gemcitabine in the treatment of genitourinary cancer. Semin Oncol 2002; 29 (1 Suppl 3): 40-45.
60. Sengelov L, Kamby C, von der Maase H. Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol 2001; 39: 634-642.
61. Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 2002; 3 (12): 738-747.
62. Calabrò F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 2002; 20 (3): 158-166.
63. Calabrò F, Sternberg CN. High-risk metastatic urathelial cancer: chances for cure? Curr Opin Urol 2002; 12 (5): 441-448.
64. Bellmunt J, Albanell J, Gallego OS et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992; 70: 1974-1979.
65. Waxman J, Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 1993; 19 (suppl. C): 21-25.
66. Sternberg CN. Gemcitabine in Bladder Cancer. Semin Oncol 2000; 27 (1): 31-39.
67. von der Maase H. Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther 2003; 3: 11-19.
68. Misset JL. Brief communication: Use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer. Semin Oncol 2002; 29 (1 Suppl 3): 36-39.
69. Sternberg CN, Vogelzang NJ. Gemcitabine, Paclitaxel, Pemetrexed and Other Newer Agents in Urothelial and Kidney Cancers. Crit Rev Oncol Hematol 2003; 46 Suppl: S105-115.
70. von der Maase H, Sengelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23 (21): 4602-4608.
71. Roth BJ, Dreicer R, Einhorn LH. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994; 12 (11): 2264-2270.
72. Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy. J Urol 1996; 156 (5): 1606-1608.
73. Murphy BA, Johnson DR, Smith J et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc Am Soc Clin Oncol 1996; 15: Abstr. 617.
74. Dreicer R, Manola J, Roth BJ et al. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group Study. J Clin Oncol 2000; 18 (5): 1058-1061.
75. Burch PA, Richardson RL, Cha SS et al. Phase II Trial of Combinatim Paclitaxel and Cisplatin in Advanced Urothelial Carcinoma (UC). J Urol 2000; 164: 1538-1542.
76. McCaffrey JA, Hilton S, Mazumdar M. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997; 15 (5): 1853-1857.
77. de Wit R, Kruit WH, Stoter G et al. Docetaxel (Taxotere): An active agent in metastatic urothelial cancer; results at a phase II study in non-chemotherapy pretreated patients. Br J Cancer 1998; 78 (10): 1342-5.
78. Sengelov L, Kamby C, Lund B, Engelholm SA. Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study. J Clin Oncol 1998; 16 (10): 3392-3397.
79. Dimopoulos MA, Bakoyannis C, Georgoulias V et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative. Ann Oncol 1999; 10 (11): 1385-1388.
80. Garcia del Muro X, Marcuello E et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 2002; 86 (3): 326-2130.
81. Sternberg CN, de Mulder P, Schomagel JH et al. Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors (EORTC protocol 30924). Eur J Cancer 2006; 42 (1): 50-54.
82. Stadler WM. Gemcitabine doublets in advanced urothelial cancer, Sem Oncol 2002; 29 (1 Suppl 3): 15-19.
83. Small EJ, Lew D, Redman BG et al. Southwest Oncology Group Study of Paclitaxel and Carboplatin for Advanced Transitional Cell Carcinoma: The Importance of Survival as a Clinical Trial End Point. J Clin Oncol 2000; 18 (13): 2537-2544.
84. Vaughn DJ, Malkowicz SB, Zoltick B et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regiment. J Clin Oncol 1998; 16 (1): 255-260.
85. Redman BG, Smith DC, Flaherty L et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Onool 1998; 16 (5): 1844-1848.
86. Sternberg CN, Calabrò F, Pizzocaro G et al. Chemotherapy with Every-2-Week Gemcitabine and Paclitaxel in Patients with Transitional Cell Carcinoma who have received prior Cisplatin-based therapy. Cancer 2001; 92 (12): 2993-2998.
87. Meluch AA, Greco FA, Burris HA et al. Paclitaxel and gemcitabine chemotherapy for adanced transitional-cell carcinoma of the urothelial tract: A Phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001; 19 (12): 3018-3024.
88. Parameswaran R, Fisch MJ, Ansari RH. A Hoosier Oncology Group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. Proc Annu Meet Am Soc Clin Oncoll 2001; 20 (1): 200a.
89. Guardino AE, Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies. Proc Annu Meet Am Soc Clin Oncol 2002; 21 (2): 150b.
90. Fechner GH, Siener R, Reimann M et al. Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma. J Urol 2002; 167 (4 Suppl): 284.
91. Kaufmann DS, Carducci MA, Kuzel T et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): A completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC). Proc Ann Meet Am Soc Clin Oncol 2002; 21 (1): 192a.
92. Manola JB, Dreicer R, Wilding G. Gemcitabine and docetaxel in advanced carcinoma of the urothelium: Reporto of a phase II Eastern Cooperative Oncology Group trial. Proc Ann Meet Am Soc Clin Oncol 2002; 21 (1): 200a.
93. Hussain M, Vaishampayan U, Smith DC. Novel gemcitabine-containing triplets in the management of urothelial cancer. Semin Oncol 2002; 29 (1 Suppl 3): 20-24.
94. Bellmunt J, Guillem V, Paz-Ares L et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 2000; 18 (18): 3247-3255.
95. Bellmunt J, de Wit R, Albiol S et al. New Drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol 2003; 2: 195-206.
96. Hussain M, Valshampayan U, Du W et al. Combination Paclitaxel, Carboplatin, and Gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncoll 2001; 19 (9): 2527-2533.
97. Bajorin DF, McCaffrey JA, Dodd PM et al. Ifosfamide, Paclitaxel, and Cisplatin for Patients with Advanced Transitional Cell Carcinoma of the Urothelial Tract: Final Report of a Phase II Trial evaluating two Dosing Schedules. Cancer 2000; 88 (7): 1671-1678.